Brain perfusion scintigraphy with99mTc-HMPAO or99mTc-ECD and123I-β-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease

[1]  J. Kornhuber,et al.  SPECT imaging of dopamine and serotonin transporters with [123I]β-CIT. Binding kinetics in the human brain , 2005, Journal of Neural Transmission / General Section JNT.

[2]  E. Länsimies,et al.  The dosimetry of iodine-123 labelled 2β-carbomethoxy-3β-(4-iodophenyl)tropane , 2004, European Journal of Nuclear Medicine.

[3]  R. Albin,et al.  Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease , 1996, Neurology.

[4]  G. Gottleib,et al.  Damage to dopamine systems differs between parkinson's disease and alzheimer's disease with parkinsonism , 1995, Annals of neurology.

[5]  Robert B. Innis,et al.  Graphical, Kinetic, and Equilibrium Analyses of in vivo [123I]β-CIT Binding to Dopamine Transporters in Healthy Human Subjects , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[6]  I. McKeith,et al.  The Clinical Diagnosis and Misdiagnosis of Senile Dementia of Lewy Body Type (SDLT) , 1994, British Journal of Psychiatry.

[7]  R. Walovitch,et al.  Intrasubject comparison between technetium-99m-ECD and technetium-99m-HMPAO in healthy human subjects. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  M. George,et al.  Neuroactivation and Neuroimaging with SPET , 1991, Springer London.

[9]  M. George,et al.  Clinical Use of SPET Imaging in Psychiatric and Neurological Disease , 1991 .

[10]  M. Drazner,et al.  Clinical and pathological aspects of parkinsonism in Alzheimer's disease. A role for extranigral factors? , 1989, Archives of neurology.

[11]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[12]  J. Kornhuber,et al.  Binding kinetics in the human brain , 2022 .